M. Kulka et al, PNAS, vol. 86, (issued Sep. 1989) pp. 6868-6872. |
E. Rapaport et al., PNAS, vol. 89 (Sep. 1992) pp. 8577-8580. |
T. Gura, Science, vol. 270 (Oct. 27, 1995) pp 575-577. |
E. Uhlmann et al., Chem. Rev., vol. 90(4) (Jun. 1990) pp. 543-584. |
J. Milligan et al., vol. 36 (14) (Jul. 9, 1993) pp. 1923-1937, J. Med. Chem. |
C. Stein et al., vol. 261 (Aug 20, 1993) Science, pp. 1004-1012 |
B. Tseng et al., Cancer Gene Therapy, vol. 1 (1) (Mar., 1994) pp. 65-71. |
R. Kole et al., Advance Drug Delivery Reviews 6, 271-286 (1991). Pre-mRNA splicing as a target for antisense obligonucleotides. |
S.H. Munroe; Antisense RNA inhibits splicing of pre-mRNA in vitro; The Embo Journal 7, pp. 2523-2532 (1988). |
P.J. Furdon and R. Kole; Inhibition of in Vitro Pre-mRNA Splicing by Antisense Deoxyoligonucleotide Analogues, Journal of Cellular Biochemistry Abstracts 18th Annual Meetings, (Mar. 27-Apr. 7, 1989). |
Y. Zhuang and A.M. Weiner; A compensatory base change in human U2 snRNA can suppress a branch site mutation, Genes & Development 3, pp. 1545-1552 (1989). |
V. Volloch et al; Inhibition of PRE-mRNA Splicing by Antisense RNA in Vitro: Effect of RNA Containing Sequences Complementary to Exons, Biochemical and Biophysical Research Communications 179, pp. 1593-1599 (1991). |
C.F. Bennett et al; Cationic Lipids Enhance Cellular Uptake and Activity of Phosphorothioate Antisense Oligonucleotides Molecular Pharmacology 41, pp. 1023-1033 (1992). |
Z. Dominski and R. Kole; Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides Proc. Natl. Acad. Sci. 90 pp. 8673-8677 (1993). |
Kole et al. Advanced Drug Delivery Reviews 6: 271-286, 1991. |
Dominski et al. Proc. Natl. Acad. Sci. 90: 8673-8677, 1993. |
Ryder et al. Nuc. Acids Res. 18(24): 7373-7379, 1990. |
Furdon et al. Nuc. Acids Res. 17(22): 9192-9204, 1989. |
Munroe, S. EMBO Journal 7(8): 2523-2532, 1988. |
Ruskin et al. Cell 43: 131-142, 1985. |